63785-87-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-1-ethylpyridin-2(1H)-one is used as a pharmaceutical candidate for its potential therapeutic applications in treating various diseases and conditions. Its antioxidant, anti-inflammatory, and anti-diabetic properties make it a promising agent for the development of new drugs.
Used in Antioxidant Applications:
BGP-15 is used as an antioxidant agent to protect cells against oxidative stress and damage. Its ability to neutralize reactive oxygen species and reduce oxidative stress makes it a potential candidate for the prevention and treatment of diseases associated with oxidative stress, such as neurodegenerative disorders and cardiovascular diseases.
Used in Anti-inflammatory Applications:
5-Bromo-1-ethylpyridin-2(1H)-one is used as an anti-inflammatory agent to reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its anti-inflammatory properties make it a potential candidate for the treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
Used in Anti-diabetic Applications:
BGP-15 is used as an anti-diabetic agent to improve insulin sensitivity and glucose metabolism. Its potential to modulate glucose homeostasis and reduce insulin resistance makes it a promising candidate for the treatment of diabetes and related metabolic disorders.
Used in Neuroprotective Applications:
5-Bromo-1-ethylpyridin-2(1H)-one is used as a neuroprotective agent to protect neurons against various forms of cellular stress and injury. Its ability to reduce inflammation and oxidative stress makes it a potential candidate for the treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Upstream product

• 81590-30-9 5-bromo-2-hydroxypyrimidine hydrobromide 
• 75-03-6 ethyl iodide 
• 13466-38-1 5-bromopyridin-2-ol 
• 74-96-4 ethyl bromide 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 13337-79-6 1-ethyl-2-pyridone 
• 1072-97-5 5-bromo-2-pyridylamine 
• 504-29-0 2-aminopyridine 

Downstream Products

• 77555-17-0 5-cyclohexyl-N-ethyl-2-pyridone 
• 77555-18-1 N,N-diethyl-6,6-dioxo-3,3-bipyridyl 
• 1349734-00-4 1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2(1H)-one 
• 1352152-30-7 (S)-tert-butyl 1-(1-amino-3-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 
• 1352152-29-4 (S)-1-amino-N-(1-cyano-2-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)cyclohexanecarboxamide 
• 1352152-31-8 (S)-tert-butyl 1-(1-cyano-2-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethylcarbamoyl)cyclohexylcarbamate 

Relevant academic research and scientific papers

TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF

The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Substituted thiazole derivative and application thereof

The invention provides a compound represented by a general formula (I), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, chemically protective form or prodrug thereof. The compound has an effect of inhibiting adenosine receptor 2a (A2a), and can be used as an antagonist of the adenosine receptor 2a (A2A) for treating tumors.

Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors

FimH is a type I fimbrial lectin located at the tip of type-1 pili of Gram-negative uropathogenic Escherichia coli (UPEC) guiding its ability to adhere and infect urothelial cells. Accordingly, blocking FimH with small molecule inhibitor is considered as a promising new therapeutic alternative to treat urinary tract infections caused by UPEC. Herein, we report that compounds having the S-glycosidic bond (thiomannosides) had improved metabolic stability and plasma exposures when dosed orally. Especially compound 5h showed the potential to inhibit biofilm formation and also to disrupt the preformed biofilm. And compound 5h showed prophylactic effect in UTI model in mice.

DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES

Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).

1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL COMPOUNDS AND USE AS SGRM MODULATORS

This specification generally relates to 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds (including salts thereof). This specification also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including treatment methods and medicament preparations), and processes for making such a compound.

Condensed derivatives of imidazole useful as pharmaceuticals

The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

SUBSTITUTED N-[1-CYANO-2-(PHENYL)ETHYL] 1-AMINOCYCLOALK-1-YLCARBOXAMIDE COMPOUNDS - 760

The present invention provides compounds of formula (I) in which, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.